Discovery and development of innovative molecular targeted therapies
| Year | Client | Period | Income | Expenses | Doc |
|---|---|---|---|---|---|
| 2009 | OSI PHARMACEUTICALS, INC. |
4th Quarter (Oct 1 - Dec 31) 4th Quarter - Report |
— | $170,000 | |
| 2009 | OSI PHARMACEUTICALS, INC. |
3rd Quarter (July 1 - Sep 30) 3rd Quarter - Report |
— | $190,000 | |
| 2009 | OSI PHARMACEUTICALS, INC. |
2nd Quarter (Apr 1 - June 30) AMENDED |
— | $120,000 | |
| 2009 | OSI PHARMACEUTICALS, INC. |
2nd Quarter (Apr 1 - June 30) 2nd Quarter - Report |
— | $120,000 | |
| 2009 | OSI PHARMACEUTICALS, INC. |
2nd Quarter (Apr 1 - June 30) 2nd Quarter - Report |
— | $120,000 | |
| 2009 | OSI PHARMACEUTICALS, INC. |
2nd Quarter (Apr 1 - June 30) AMENDED |
— | — | |
| 2009 | OSI PHARMACEUTICALS, INC. |
2nd Quarter (Apr 1 - June 30) AMENDED |
— | — |
| Client | Filings | Total Income |
|---|---|---|
| OSI PHARMACEUTICALS, INC. | 11 | — |
| Name | Disclosed Prior Position |
|---|---|
| KIMBERLY LINTHICUM | Legislative Director, Rep Bob Franks (1997-2000)Legislative Correspondent, Rep Charles Taylor (1997)Legislative Corresp… |